The effects of the loop diuretics furosemide and torasemide on diuresis in dogs and cats

被引:41
作者
Uechi, M [1 ]
Matsuoka, M [1 ]
Kuwajima, E [1 ]
Kaneko, T [1 ]
Yamashita, K [1 ]
Fukushima, U [1 ]
Ishikawa, Y [1 ]
机构
[1] Kitasato Univ, Vet Teaching Hosp, Towada, Aomori 0348628, Japan
关键词
diuretic agent; feline; heart failure; renal function; urine;
D O I
10.1292/jvms.65.1057
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Torasemide is a new loop diuretic that combines the effects of furosemide and spironolactone. There are no reports on the effects of torasemide in cats and dogs. This study compared the diuretic effects of furosemide and torasemide in cats and dogs. Cats with pressure overload cardiac hypertrophy were given oral placebo, torasemide 0.3 mg/kg, or furosemide 1 mg/kg or 3 mg/kg. Control and mitral regurgitation dogs were given oral placebo, torasemide 0.2 mg/kg, and furosemide 2 mg/kg for 7 days. Urine samples were obtained at baseline and 1, 2, 3, 4, 5, 6, 8, 12, and 24 hr after each drug dose. Urine volume and urine Na+ and K+ were measured. Both furosemide and torasemide increased urine volume I hr after administration. Furosemide caused a dose-dependent increase in urine volume that peaked at 2-3 hr in cats and dogs. The diuretic effect of furosemide disappeared 6 hr after administration, while that of torasemide peaked 2-4 hr after administration and persisted for 12 hr in cats and dogs. In MR dogs, torasemide for 7 days significantly decreased urine potassium excretion. Plasma aldosterone increased with torasemide, whereas there was no change with furosemide. In conclusion, about 1/10 concentration of torasemide was as potent as furosemide and had a longer diuretic effect in cats and dogs. These data suggest that torasemide is useful for treating congestive heart failure or edema in cats and dogs.
引用
收藏
页码:1057 / 1061
页数:5
相关论文
共 20 条
[1]   BUMETANIDE AND FUROSEMIDE IN HEART-FAILURE [J].
BRATER, DC ;
DAY, B ;
BURDETTE, A ;
ANDERSON, S .
KIDNEY INTERNATIONAL, 1984, 26 (02) :183-189
[2]  
BRAUNWALD E, 1997, HEART DIS TXB CARDIO, P1
[3]  
DELARGE J, 1988, ARZNEIMITTEL-FORSCH, V38-1, P144
[4]   FUROSEMIDE ABSORPTION IN PATIENTS WITH CIRRHOSIS [J].
FREDRICK, MJ ;
POUND, DC ;
HALL, SD ;
BRATER, DC .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (03) :241-247
[5]  
GHYS A, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1520
[6]   Torsemide inhibits aldosterone secretion in vitro [J].
Goodfriend, TL ;
Ball, DL ;
Oelkers, W ;
Bähr, V .
LIFE SCIENCES, 1998, 63 (03) :PL45-PL50
[7]  
LESNE M, 1988, ARZNEIMITTEL-FORSCH, V38-1, P160
[8]  
PATTERSON JH, 1994, PHARMACOTHERAPY, V14, P514
[9]   THE PHARMACODYNAMICS OF INTRAVENOUS AND ORAL TORSEMIDE IN PATIENTS WITH CHRONIC RENAL-INSUFFICIENCY [J].
RUDY, DW ;
GEHR, TWB ;
MATZKE, GR ;
KRAMER, WG ;
SICA, DA ;
BRATER, DC .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (01) :39-47
[10]   Downregulation of ANG II receptor is associated with compensated pressure-overload hypertrophy in the young dog [J].
Schultz, D ;
Su, XF ;
Wei, CC ;
Bishop, SP ;
Powell, P ;
Hankes, GH ;
Dillon, AR ;
Rynders, P ;
Spinale, FG ;
Walcott, G ;
Ideker, R ;
Dell'Italia, LJ .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2002, 282 (02) :H749-H756